<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489630</url>
  </required_header>
  <id_info>
    <org_study_id>08302015</org_study_id>
    <nct_id>NCT02489630</nct_id>
  </id_info>
  <brief_title>Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department</brief_title>
  <official_title>Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carilion Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virginia Polytechnic Institute and State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Memphis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carilion Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the use of low doses of ketamine, along with opiate pain medication,&#xD;
      is more effective at controlling the acute pain of patients in the emergency department than&#xD;
      opiate pain medication alone. In addition, this study examines whether patients treated with&#xD;
      low doses of ketamine, along with opiate pain medication, will require less opiate pain&#xD;
      medication to control their pain, and whether these patients are equally happy with their&#xD;
      pain control as patients who receive only opiate pain medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double blinded, placebo controlled study investigates the use of low-dose&#xD;
      ketamine, in conjunction to standard opiate treatment, as compared to placebo plus standard&#xD;
      opiate treatment, for acute painful conditions in the ED setting. The investigators&#xD;
      hypothesize that patients treated with ketamine will require less opiate for similar levels&#xD;
      of pain relief up to 2 hours from initiation of treatment, with similar levels of patient&#xD;
      satisfaction and an acceptable side effect profile.&#xD;
&#xD;
      Once seen by a physician, potential patients will receive provider-determined opiate&#xD;
      treatment for their painful condition, prior to the informed consent process to ensure that&#xD;
      treatment is not delayed. Once identified for inclusion, patients will receive informed&#xD;
      consent and, upon consent, will subsequently be randomized through block randomization into&#xD;
      one of two study groups. Each study group will contain at least 50 subjects. Randomization&#xD;
      will be determined using a table of random numbers, using a restricted randomization scheme&#xD;
      to ensure roughly equal numbers in each group. Group assignments will be sealed in opaque&#xD;
      envelopes to be opened sequentially by the investigators. Group assignments will not indicate&#xD;
      whether it is the treatment or the control group. At this time (T0), an initial NRS-11 score&#xD;
      will be obtained. The NRS-11 is an 11-point scale on which patients rate their level of pain&#xD;
      from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). If, after initial analgesic, pain level&#xD;
      is &lt;6, patients will be asked again in 15 min. If at this time it is still &lt;6, they will not&#xD;
      proceed in the study. The intervention group will receive 0.1 mg/kg of ketamine given over 1&#xD;
      minute, and the control group will receive an equivalent volume of normal saline; both groups&#xD;
      will have received a provider-determined dose of opiate analgesia prior to enrollment. At&#xD;
      thirty-minute intervals, subjects will be asked their level of pain, if they need more pain&#xD;
      control and will be evaluated for the presence of side effects (hallucinations, dysphoria,&#xD;
      weakness, diplopia, nausea, vomiting, dizziness, itching and bradypnea) as well as sedation&#xD;
      as defined by Ramsay score of greater than 2. Repeat doses of pain medication will be given&#xD;
      as 0.05 mg/kg morphine or equivalent dose of opioid analgesic. Total opiate dosage and number&#xD;
      of repeat doses given at the end of 120 minutes will be recorded. At each time interval, as&#xD;
      well as at the end of 120 minutes (T120), patient satisfaction with pain control will be&#xD;
      recoded on the 4-point Likert scale, with 0 being &quot;completely unsatisfied&quot; and 3 being &quot;very&#xD;
      satisfied&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Level of Pain Control as Reported on the NRS-11</measure>
    <time_frame>20 min pre-medication administration, 0 min, 30 min, 60 min, 90 min, 120 min post medication administration</time_frame>
    <description>Patient-reported pain scores on numerical rating scale (NRS) -11 pain scale (where 0 indicates no pain at all, 10 indicates the most severe pain). &quot;Initial&quot; group were patients enrolled and randomized in to the study, assessments were taken at the time of enrollment/randomization in to the study (up to 20 min prior to T=0). T = 0 min assessments were conducted at the time of medication administration (study allowed for an up to 20-minute delay in receiving study drug in order to retrieve study drug from secure storage, nursing documentation and patient verification prior to administration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient Satisfaction With Pain Control on a 1-4 Likert Scale</measure>
    <time_frame>0 min, 30 min, 60 min, 90 min, 120 min post medication administration</time_frame>
    <description>Patient-reported score regarding satisfaction with pain control, reported on a 4-point Likert scale (1-4, where 1 is the lowest satisfaction score possible and 4 is the highest satisfaction score possible). No data is reported for T = 0 min, as that assessment was conducted concurrently with initial medication dosing (since patients were at that point receiving their first pain control efforts, they could not yet assess their satisfaction with those efforts).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Opiate Dosage Between Study Arms in Morphine Equivalents</measure>
    <time_frame>20 mins pre-medication administration, 0 min, 30 min, 60 min, 90 min, 120 min post medication administration</time_frame>
    <description>Average difference in opiate dosage between study arms, calculated in morphine equivalents. &quot;Initial&quot; indicates at first dose of opioid administration, up to 20 mins prior to study drug administration, and from 0 min to 120 min after study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Acute Pain</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg ketamine + opiate analgesic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.1 mL/kg normal saline + opiate analgesic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.1mg/kg ketamine IV</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>1ml/kg normal saline placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NS, saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>opiate analgesic</intervention_name>
    <description>0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request</description>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than 18 years but less than 70 years old.&#xD;
&#xD;
          -  Exhibiting pain defined on a numerical rating scale (NRS-11 [Farrar et al. 2001])&#xD;
             score of equal to or greater than 6 out of 10&#xD;
&#xD;
          -  Deemed by the treating EM physician to require opioid analgesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Respiratory, hemodynamic or neurologic compromise, as determined by observation of&#xD;
             signs of respiratory distress, systolic blood pressure less than 90 mmHg or&#xD;
             systolic/diastolic blood pressure greater than 160/90, or a Glasgow -Coma Score less&#xD;
             than 15.&#xD;
&#xD;
          -  A history of chronic ventilation, dialysis or with previously diagnosed cirrhosis or&#xD;
             hepatitis by istory.&#xD;
&#xD;
          -  Active psychosis.&#xD;
&#xD;
          -  Clinical intoxication.&#xD;
&#xD;
          -  Known sensitivity to any study drug.&#xD;
&#xD;
          -  An inability to understand the NRS-11 pain measurement scale.&#xD;
&#xD;
          -  Presentation with headache or chest pain.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  A lack of decision-making capacity.&#xD;
&#xD;
          -  A pain score less than 6 on the NRS-11 scale.&#xD;
&#xD;
          -  A concern by the treating physician or study personnel of current or prior history of&#xD;
             narcotic abuse, or other secondary gain.&#xD;
&#xD;
          -  Previously participated in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey R Heitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <reference>
    <citation>Ahern TL, Herring AA, Stone MB, Frazee BW. Effective analgesia with low-dose ketamine and reduced dose hydromorphone in ED patients with severe pain. Am J Emerg Med. 2013 May;31(5):847-51. doi: 10.1016/j.ajem.2013.02.008. Epub 2013 Apr 18.</citation>
    <PMID>23602757</PMID>
  </reference>
  <reference>
    <citation>Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014 Nov;21(11):1193-202. doi: 10.1111/acem.12510.</citation>
    <PMID>25377395</PMID>
  </reference>
  <reference>
    <citation>Galinski M, Dolveck F, Combes X, Limoges V, Sma√Øl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.</citation>
    <PMID>17499654</PMID>
  </reference>
  <reference>
    <citation>Jennings PA, Cameron P, Bernard S, Walker T, Jolley D, Fitzgerald M, Masci K. Morphine and ketamine is superior to morphine alone for out-of-hospital trauma analgesia: a randomized controlled trial. Ann Emerg Med. 2012 Jun;59(6):497-503. doi: 10.1016/j.annemergmed.2011.11.012. Epub 2012 Jan 13.</citation>
    <PMID>22243959</PMID>
  </reference>
  <reference>
    <citation>Johansson P, Kongstad P, Johansson A. The effect of combined treatment with morphine sulphate and low-dose ketamine in a prehospital setting. Scand J Trauma Resusc Emerg Med. 2009 Nov 27;17:61. doi: 10.1186/1757-7241-17-61.</citation>
    <PMID>19943920</PMID>
  </reference>
  <reference>
    <citation>Kissin I, Bright CA, Bradley EL Jr. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg. 2000 Dec;91(6):1483-8.</citation>
    <PMID>11094005</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <results_first_submitted>February 10, 2020</results_first_submitted>
  <results_first_submitted_qc>February 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2021</results_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02489630/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02489630/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>0.1 mg/kg ketamine + opiate analgesic&#xD;
Ketamine: 0.1mg/kg ketamine IV&#xD;
opiate analgesic: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.1 mL/kg normal saline + opiate analgesic&#xD;
Normal Saline: 1ml/kg normal saline placebo&#xD;
opiate analgesic: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Oversedation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time to med. admin. &gt; protocol limit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>0.1 mg/kg ketamine + opiate analgesic&#xD;
Ketamine: 0.1mg/kg ketamine IV&#xD;
opiate analgesic: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.1 mL/kg normal saline + opiate analgesic&#xD;
Normal Saline: 1ml/kg normal saline placebo&#xD;
opiate analgesic: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.77" lower_limit="18" upper_limit="69"/>
                    <measurement group_id="B2" value="41.43" lower_limit="18" upper_limit="69"/>
                    <measurement group_id="B3" value="42.46" lower_limit="18" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Level of Pain Control as Reported on the NRS-11</title>
        <description>Patient-reported pain scores on numerical rating scale (NRS) -11 pain scale (where 0 indicates no pain at all, 10 indicates the most severe pain). &quot;Initial&quot; group were patients enrolled and randomized in to the study, assessments were taken at the time of enrollment/randomization in to the study (up to 20 min prior to T=0). T = 0 min assessments were conducted at the time of medication administration (study allowed for an up to 20-minute delay in receiving study drug in order to retrieve study drug from secure storage, nursing documentation and patient verification prior to administration).</description>
        <time_frame>20 min pre-medication administration, 0 min, 30 min, 60 min, 90 min, 120 min post medication administration</time_frame>
        <population>Total number of study subjects; received intervention or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Patients receiving study intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients not receiving study intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Level of Pain Control as Reported on the NRS-11</title>
          <description>Patient-reported pain scores on numerical rating scale (NRS) -11 pain scale (where 0 indicates no pain at all, 10 indicates the most severe pain). &quot;Initial&quot; group were patients enrolled and randomized in to the study, assessments were taken at the time of enrollment/randomization in to the study (up to 20 min prior to T=0). T = 0 min assessments were conducted at the time of medication administration (study allowed for an up to 20-minute delay in receiving study drug in order to retrieve study drug from secure storage, nursing documentation and patient verification prior to administration).</description>
          <population>Total number of study subjects; received intervention or placebo.</population>
          <units>Units on a scale (1-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.38" spread="0.97"/>
                    <measurement group_id="O2" value="9.44" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 0 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="1.53"/>
                    <measurement group_id="O2" value="8.10" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="2.58"/>
                    <measurement group_id="O2" value="2.27" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" spread="2.79"/>
                    <measurement group_id="O2" value="6.18" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="2.63"/>
                    <measurement group_id="O2" value="6.21" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="2.95"/>
                    <measurement group_id="O2" value="5.68" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Patient Satisfaction With Pain Control on a 1-4 Likert Scale</title>
        <description>Patient-reported score regarding satisfaction with pain control, reported on a 4-point Likert scale (1-4, where 1 is the lowest satisfaction score possible and 4 is the highest satisfaction score possible). No data is reported for T = 0 min, as that assessment was conducted concurrently with initial medication dosing (since patients were at that point receiving their first pain control efforts, they could not yet assess their satisfaction with those efforts).</description>
        <time_frame>0 min, 30 min, 60 min, 90 min, 120 min post medication administration</time_frame>
        <population>Study subject-reported satisfaction with their pain control beginning at T = 30 minutes post-medication administration. Some study subjects were discharged, admitted or went to the operating room prior to this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Patients receiving study intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients not receiving study intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient Satisfaction With Pain Control on a 1-4 Likert Scale</title>
          <description>Patient-reported score regarding satisfaction with pain control, reported on a 4-point Likert scale (1-4, where 1 is the lowest satisfaction score possible and 4 is the highest satisfaction score possible). No data is reported for T = 0 min, as that assessment was conducted concurrently with initial medication dosing (since patients were at that point receiving their first pain control efforts, they could not yet assess their satisfaction with those efforts).</description>
          <population>Study subject-reported satisfaction with their pain control beginning at T = 30 minutes post-medication administration. Some study subjects were discharged, admitted or went to the operating room prior to this time point.</population>
          <units>Units on a scale (1-4)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T = 30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.88"/>
                    <measurement group_id="O2" value="2.27" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.76"/>
                    <measurement group_id="O2" value="2.33" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="0.65"/>
                    <measurement group_id="O2" value="2.38" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T = 120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.67"/>
                    <measurement group_id="O2" value="2.52" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Opiate Dosage Between Study Arms in Morphine Equivalents</title>
        <description>Average difference in opiate dosage between study arms, calculated in morphine equivalents. &quot;Initial&quot; indicates at first dose of opioid administration, up to 20 mins prior to study drug administration, and from 0 min to 120 min after study drug administration.</description>
        <time_frame>20 mins pre-medication administration, 0 min, 30 min, 60 min, 90 min, 120 min post medication administration</time_frame>
        <population>Total number of patients receiving study intervention or placebo (less the two patients who were enrolled but did not receive medication within the protocol-defined time limit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Patients receiving study intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients not receiving study intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Opiate Dosage Between Study Arms in Morphine Equivalents</title>
          <description>Average difference in opiate dosage between study arms, calculated in morphine equivalents. &quot;Initial&quot; indicates at first dose of opioid administration, up to 20 mins prior to study drug administration, and from 0 min to 120 min after study drug administration.</description>
          <population>Total number of patients receiving study intervention or placebo (less the two patients who were enrolled but did not receive medication within the protocol-defined time limit.</population>
          <units>Milligrams of Morphine Equivalent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial Narcotic Dosage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="2.77"/>
                    <measurement group_id="O2" value="5.83" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Narcotic Dosage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="5.83"/>
                    <measurement group_id="O2" value="12.81" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Collection approach for adverse events: regular investigator assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Patients receiving study intervention</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients not receiving study intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was conducted in a busy ED in the general patient population, without special conditions, locations, or providers for study patients. The cohort includes subjects with chronic pain and long-term outpatient opioid use, as well as patients with new-onset acute pain; it is possible that the former patient population may react quite differently to the adjunctive ketamine usage than the latter.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen J Bowers, co-PI</name_or_title>
      <organization>Virginia Tech SOM / Carilion Clinic (prior)</organization>
      <phone>678-591-7280</phone>
      <email>bowerskj@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

